Turner William D. 4

4 · Vera Therapeutics, Inc. · Filed Feb 6, 2026

AI-generated summary of this filing

Updated Feb 7, 2026

Vera Therapeutics (VERA) Chief Regulatory Officer William D. Turner Receives Award

What Happened

William D. Turner, Chief Regulatory Officer of Vera Therapeutics (VERA), was granted equity awards on 2026-02-04: 25,000 restricted stock units (RSUs) and a 50,000-share derivative award (stock option/award). Both were reported as acquired at $0.00 (standard compensation grants), totaling 75,000 potential shares.

Key Details

Transaction date: 2026-02-04. Form 4 filed: 2026-02-06.
Price: $0.00 per share (award/grant — compensation, not an open-market purchase).
Shares acquired: 25,000 RSUs (non-derivative) + 50,000 derivative award (option/award) = 75,000 potential shares.
Shares owned after transaction: Not specified in the provided filing.
Footnotes:
- F1: The 25,000 RSUs vest 25% on each of Feb 20, 2027, 2028, 2029 and 2030, subject to continued service.
- F2: The 50,000 derivative award vests 1/48th on March 4, 2026 and 1/48th monthly thereafter, subject to continued service.
Filing timeliness: No late-filing flag indicated in the supplied data.

Context

These entries are compensation grants (awards), not purchases or sales — common for employee compensation and not a direct market signal of buying or selling.
The 50,000-share item is a derivative award (vesting schedule described above); it does not mean immediate ownership of all shares until vested/exercised.
No indication in the filing that any shares were sold immediately (no cashless exercise or market sale reported).

Form 4

Period: 2026-02-04

Chief Regulatory Officer

Transactions

Award
Class A Common Stock
[F1]
2026-02-04+25,000→ 47,500 total
Award
Stock Option (right to buy)
[F2]
2026-02-04+50,000→ 50,000 total
Exercise: $42.74Exp: 2036-02-03→ Class A Common Stock (50,000 underlying)

Footnotes (2)

[F1]Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.
[F2]1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

Signature

/s/ Joseph R. Young, Attorney-in-Fact|2026-02-06

1 file